Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Blood

Volumn 118, Issue 20, 2011, Pages 5593-5603

  Shen, Yang ^a   Zhu, Yong Mei ^a   Fan, Xing ^a   Shi, Jing Yi ^a   Wang, Qin Rong ^a   Yan, Xiao Jing ^a   Gu, Zhao Hui ^a   Wang, Yan Yan ^a   Chen, Bing ^a   Jiang, Chun Lei ^a   Yan, Han ^a   Chen, Fei Fei ^b   Chen, Hai Min ^a   Chen, Zhu ^a   Jin, Jie ^b   Chen, Sai Juan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADDITIONAL SEX COMBS LIKE 1; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; NUCLEOPHOSMIN; OXIDOREDUCTASE; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHROMOSOME 11Q; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MIXED LINEAGE LEUKEMIA GENE; ONCOGENE N RAS; PRIORITY JOURNAL; PROGNOSIS; TEN ELEVEN 2 GENE; WILM TUMOR 1 GENE;

EID: 81555228423     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-343988     Document Type: Article

References (53)

1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
2. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109(3):874-885. (Pubitemid 46220630)
3. Mills KI, Kohlmann A, Williams PM, et al. Microarraybased classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AMLtransformation of myelodysplastic syndrome.Blood. 2009;114(5):1063-1072.
4. Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood. 2006;108(13):4146-4155. (Pubitemid 44913286)
5. Weltermann A, Fonatsch C, Haas OA, et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia.2004;18(2):293- 302. (Pubitemid 38240045)
6. Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.Blood. 2003;102(2):462-469. (Pubitemid 36841961)
7. Flach J, Dicker F, Schnittger S, et al. An accumulation of cytogenetic and molecular geneticevents characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecularmutation analysis and SNP microarray profiling.Leukemia. 2011;25(4):713-718.
8. Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program. 2010:47-55.
9. Gonzalez Garcia JR, Meza-Espinoza JP. Use of the International System for Human Cytogenetic Nomenclature (ISCN) [Letter to the Editor]. Blood.2006;108(12):3952-3953; author reply 3953.
10. Miyazaki Y, Kuriyama K, Miyawaki S, et al. Cytogeneti cheterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol.2003;120(1):56-62. (Pubitemid 36056909)
11. Singh H, Werner L, Deangelo D, et al. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010;85(12):956-957.
12. Ohnishi K. PML-RARalpha inhibitors (ATRA, tamibaroten,arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol. 2007;12(5):313-317. (Pubitemid 47573414)
13. Ravindranath Y, Gregory J, Feusner J. Treatment of acute promyelocytic leukemia in children: arsenic or ATRA. Leukemia. 2004;18(10):1576-1577. (Pubitemid 39386331)
14. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxidebasedtherapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A.2009;106(9):3342-3347.
15. Prébet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion(16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747-4753.
16. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358(18):1909-1918. (Pubitemid 351620111)
17. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006; 20(6):965-970. (Pubitemid 43797286)
18. Wang YY, Zhao LJ, Wu CF, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2011;108(6):2450-2455.
19. Tashiro H, Shirasaki R, Oka Y, et al. FLT3 internal tandem duplication is associated with a high relapse rate and central nervous system involvement in acute promyelocytic leukemia cases: single institutional analysis. Eur J Haematol. 2011;86(3):272-273.
20. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650-665. (Pubitemid 37328820)
21. Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev. 2007; 17(1):15-22. (Pubitemid 46109294)
22. Dicker F, Haferlach C, Sundermann J, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia. 2010;24(8):1528- 1532.
23. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006; 20(6):965-970. (Pubitemid 43797286)
24. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113-2119. (Pubitemid 41291728)
25. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740- 3746.
26. Fuchs O, Provaznikova D, Kocova M, et al. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis. 2008;40(3):401- 405.
27. Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW. Combined testing for CCAAT/ enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features. Leuk Res. 2011;35(2):200-207.
28. Pabst T, Mueller BU, Zhang P, et al. Dominantnegative mutations of CEBPA, encoding CCAAT/ enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3): 263-270. (Pubitemid 32201846)
29. Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2010; 116(5):702-710.
30. Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116(20):4086- 4094.
31. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010;115(14):2749- 2754.
32. Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010; 116(25):5486-5496.
33. Damm F, Thol F, Hollink I, et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. [prepublished on June 7, 2011]. Leukemia. doi:10.1038/leu.2011.142.
34. Maitta RW, Cannizzaro LA, Ramesh KH. Association of MLL amplification with poor outcome in acute myeloid leukemia. Cancer Genet Cytogenet. 2009;192(1):40-43.
35. Sárová I, Brezinova J, Zemanova Z, et al. A partial nontandem duplication of the MLL gene in four patients with acute myeloid leukemia. Cancer Genet Cytogenet. 2009;195(2):150-156.
36. Kourlas PJ, Strout MP, Becknell B, et al. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2000;97(5):2145-2150. (Pubitemid 30134036)
37. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
38. Nyvold CG, Stentoft J, Braendstrup K, et al. Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: Biological and clinical implications. Leukemia. 2006;20(11): 2051-2054. (Pubitemid 44614901)
39. Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2010;56-61.
40. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4):309-315.
41. Claus R, Plass C, Armstrong SA, Bullinger L. DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol. 2010; 6(9):1415-1431.
42. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13-27.
43. Meilinger D, Fellinger K, Bultmann S, et al. Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in embryonic stem cells. EMBO Rep. 2009;10(11):1259-1264.
44. Whitman SP, Hackanson B, Liyanarachchi S, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008;112(5):2013- 2016.
45. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program. 2008;1-11.
46. Kuendgen A, Germing U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat Rev. 2009;35(2):97-120.
47. Dupont M. Rapid identification of frequent MLL rearrangements in hematologic malignancies by multiplex RT-PCR in a single assay [Letter to the Editor]. Leukemia. 2002;16(8):1574; author reply 1575-1576.
48. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649. (Pubitemid 46594039)
49. Gill RD. Multistate life-tables and regression models. Math Popul Stud. 1992;3(4):259-276. (Pubitemid 23366572)
50. Liu YR, Wang YZ, Chen SS, et al. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2007;28(11):731-736.
51. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009; 23(7):1343-1345.
52. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
53. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal- center origin. Nat Genet. 2010;42(2):181-185.